Aberrant methylation of the promoter regions of the SOX7 and p15INK4b genes and Wnt signaling pathway antagonists in patients with acute myeloid leukemias


Cite item

Full Text

Abstract

Aim. To investigate the methylation status of the SOX7 and p15NK4b genes and Wnt signaling pathway antagonists in patients with acute myeloid leukemia (AML) in order to assess the association of the rate of aberrant methylation (AM) with the morphological variant and pattern of chromosomal aberrations, as well as the impact of the methylation status on survival. Subjects and methods. The data of 57 AML patients aged 20 to 79 years were analyzed. The methylation status of the genes was studied by methylation-specific polymerase chain reaction. Results. The signs of the AM of ≥1 gene were detected in 52 (91.2%) of the 57 patients. The most common finding was AM of simultaneously 2 or 3 genes: in 29.8 and 21.1% of the patients, respectively. Concurrent methylation of 3-5 genes proved to be a more frequent finding in AML patients with myelodysplasia: in 7 (70%) of 10 patients. The proportion of patients with methylation of 5 genes was considerably higher in a group of patients with a complex karyotype: 50% versus 8.3% among other patients (odds ratio: 11.0; 95% confidence interval 2.0 to 61.6; p=0.01). There were no differences in the median overall and relapse-free survival rates in patients with a normal karyotype and without FLT3 and NPM mutations, who received induction therapy, in relation to the number of genes with AM. Conclusion. AM of the p15NK4b and SOX7 genes and Wnt signaling pathway antagonists is detected in the majority of patients with AML, which allows hypomethylating agents to be recommended for the treatment of patients who cannot use intensive cytostatic therapy for different reasons. The detection of a large number of genes with the aberrant methylation status in most AML patients with myelodysplasia or a complex karyotype serves as the basis for initiating trials to evaluate the efficiency of a combination of 5-azacytidine and cytostatics.

References

  1. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823-2829. doi: 10.1182/blood.v97.9.2823
  2. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13-27. doi: 10.1016/j.ccr.2009.11.020
  3. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21. doi: 10.1101/gad.947102
  4. Wang H, Fan R, Wang X-Q, Wu DP, Lin GW, Xu Y, Li WY. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome. Ann Hematol. 2013;92(2):199-209. doi: 10.1007/s00277-012-1595-y
  5. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG, Osieka R, Galm O. Epigenetic inactivation of secreted frizzled-related proteins in acute myeloid leukaemia. Br J Haematol. 2008;142(5):745-753. doi: 10.1111/j.1365-2141.2008.07242.x
  6. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P, Moscardo F, Sanz GF, Sanz MA. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia. 2009;23(9):1658-1666. doi: 10.1038/leu.2009.86
  7. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010;51(9): 1711-1719. doi: 10.3109/10428194.2010.49650
  8. Hou H, Kuo Y, Liu C, Lee MC, Tang JL, Chen CY, Chou WC, Huang CF, Lee FY, Liu MC, Yao M, Tien HF. Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia. Br J Cancer. 2011;105(12): 1927-1933. doi: 10.1038/bjc.2011.471
  9. Ghasemi A, Rostami S, Chahardouli B, Ghandforosh NA, Ghotaslou A, Nadali F. Study of SFRP1 and SFRP2 methylation status in patients with de novo acute myeloblastic leukemia. Int J Hematol Oncol Stem Cell Res. 2015;9(1):15-21.
  10. Грицаев С.В., Сидорова Ж.Ю. Капустин С.И., Кострома И.И., Потихонова Н.А., Мартынкевич И.С., Блинов М.Н., Абдулкадыров К.М. Анализ статуса метилирования генов р15INK4B и SOX7 у больных миелодиспластическим синдромом и острым миелоидным лейкозом. Гематология и трансфузиология. 2015;60(1):12-17.
  11. Abaigar M, Ramos F, Benito R, Diez-Campelo M, Sanchez-del-Real J, Hermosin L, Rodríguez JN, Aguilar C, Recio I, Alonso JM, de las Heras N, Megido M, Fuertes M, del Cañizo MC, Hernández-Rivas JM. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Ann Hematol. 2013;92(11):1543-1552. doi: 10.1007/s00277-013-1799-9
  12. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010;51(1):73-78. doi: 10.3109/10428190903318329
  13. Krug U, Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Röllig C, Thiede C, Noppeney R, Stelljes M, Büchner T, Koschmieder S, Dührsen U, Serve H, Ehninger G, Berdel WE, Müller-Tidow C. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study. PLOS ONE. 2012;7(12):e52695. doi: 10.1371/journal.pone. 0052695
  14. Herman JG, Graff JR, Myohanen S., Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. PNAS. 1996;93(18):9821-9826. doi: 10.1073/pnas.93.18.9821
  15. Fan R, Zhang LY, Wang H, Yang B, Han T, Zhao XL, Wang W, Wang XQ, Lin GW. Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. Tohoku J Exp Med. 2012;227(2): 119-128. doi: 10.1620/tjem.227.119
  16. Wang H, Fan R, Wang XQ, Wu DP, Lin GW, Xu Y, Li WY. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome. Ann Hematol. 2013;92(2):199-209. doi: 10.1007/s00277-012-1595-y
  17. Kroeger H, Jelinek J, Estґecio MRH, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112(4):1366-1137. doi: 10.1182/blood-2007-11-126227
  18. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91(8):2985-2990. doi: 10.1016/0145-2126(94)90231-3
  19. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17(9):1813-1819. doi: 10.1038/sj.leu.2403054
  20. Chim CS, Tam CYY, Liang R, Kwong YL. Methylation of p15 and p16 in adult acute leukemia: lack of prognostic significance. Cancer. 2001;91(12):2222-2229. doi: 10.1002/1097-0142(20010615)91:12<2222::aid-cncr1252>3.0.co;2-r
  21. Chim CS, Liang R, Tam CYY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol. 2001;19(7):2033-2040. doi: 10.1002/1097-0142(20010615)91:12<2222::aid-cncr1252>3.3.co;2-i
  22. Grovdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res. 2007;13(23):7107-7112. doi: 10.1158/1078-0432.ccr-07-1193
  23. Mikesch J, Steffen B, Berdel W, Serve H, Müller-Tidow C. The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia. 2007;21(8):1638-1647. doi: 10.1038/sj.leu.2404732
  24. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56(4):722-727.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies